LGD-6972 Could Drive Partnership; Roth Keeps Ligand Pharma (LGND) at 'Buy'
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $92 target price on Ligand Pharmaceuticals (Nasdaq: LGND) following data from the Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
